<?xml version="1.0" encoding="UTF-8"?>
<p>The proteasome-inhibitor bortezomib (bort) can selectively deplete proliferating alloreactive T lymphocytes, reduce Th1 cytokines and Interleukin-6 levels, and block antigen-presenting cell (APC) activation.
 <sup>
  <xref rid="b3-1030522" ref-type="bibr">3</xref>â€“
  <xref rid="b6-1030522" ref-type="bibr">6</xref>
 </sup> It can also spare regulatory T cells (Tregs) that are relevant in GvHD control.
 <sup>
  <xref rid="b7-1030522" ref-type="bibr">7</xref>
 </sup> Administered early after graft infusion, short-course bort can control GvHD in major histocompatibility complex (MHC)-mismatched mouse HSCT and maintain graft-
 <italic>versus</italic>-tumor responses,
 <sup>
  <xref rid="b6-1030522" ref-type="bibr">6</xref>,
  <xref rid="b8-1030522" ref-type="bibr">8</xref>,
  <xref rid="b9-1030522" ref-type="bibr">9</xref>
 </sup> while avoiding the pro-inflammatory colonic toxicity of delayed or prolonged bort.
 <sup>
  <xref rid="b5-1030522" ref-type="bibr">5</xref>,
  <xref rid="b8-1030522" ref-type="bibr">8</xref>,
  <xref rid="b10-1030522" ref-type="bibr">10</xref>
 </sup>
</p>
